Durvalumab,etoposide,olaparib
Astrazeneca,Merck
['trident', 'durva', 'sclc', 'olaparib']
dr. afshin dowlati at #asco23 discussing poster on trident #sclc study of durvalumab plus olaparib maintenance therapy. at 1y. 18% alive with no pd. any better than io alone? cautions about how to interpret a single arm phase ii - randomized studies much more informative. 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown, Co-Host Official @IASLC Podcast, #ITYSL, #HereWeGo